



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Baiyang WANG

Appl. No.: 10/816,938

Filed: April 5, 2004

For: **Tissue Factor Antibodies and
Uses Thereof**

Confirmation No.: 3825

Art Unit: 1632

Examiner: To Be Assigned

Atty. Docket: 1861.1670002/JUK/AWL

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

No copies of U.S. patents and patent application publications cited on the attached Form PTO-1449 are submitted in accordance with 1276 OG 55 because this application was filed after June 30, 2003.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicant's undersigned representative submits the following discussion of the relevance of the non-English language documents **AL1** and **AN2** cited on Form PTO-1449:

Document **AL1** is in a foreign language. An English language abstract of document **AL1** is attached as document **AR10**.

Document **AN2** is in a foreign language. An English language abstract of document **AN2** is attached as document **AS10**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Judith U. Kim
Attorney for Applicant
Registration No. 40,679

Date: November 9, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Baiyang WANG

Appl. No.: 10/816,938

Filed: April 5, 2004

For: **Tissue Factor Antibodies and
Uses Thereof**

Confirmation No.: 3825

Art Unit: 1632

Examiner: To Be Assigned

Atty. Docket: 1861.1670002/JUK/AWL

First Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicant's Information Disclosure Statement filed herewith in connection with the above-captioned application. Copies of the documents are submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Judith U. Kim
Attorney for Applicant
Registration No. 40,679

Date: November 9, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

				Page 1 of 10			
FORM PTO-1449				ATTY. DOCKET NO. 1861.1670002/JUK/AWL			
INFORMATION DISCLOSURE STATEMENT				APPLICATION NO. 10/816,938			
U.S. PATENT DOCUMENTS				FIRST NAMED INVENTOR Wang, B.			
U.S. PATENT DOCUMENTS				FILING DATE April 5, 2004			
U.S. PATENT DOCUMENTS				ART UNIT 1632			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,110,730	05/05/1992	Edgington <i>et al.</i>			06/25/1987
	AB1	5,223,427	06/29/1993	Edgington <i>et al.</i>			03/09/1988
	AC1	5,437,864	08/01/1995	Edgington <i>et al.</i>			11/16/1992
	AD1	5,506,134	04/09/1996	Soule <i>et al.</i>			09/13/1991
	AE1	5,622,931	04/22/1997	Edgington <i>et al.</i>			04/29/1992
	AF1	5,877,289	03/02/1999	Thorpe <i>et al.</i>			06/07/1995
	AG1	5,986,065	11/16/1999	Wong <i>et al.</i>			03/10/1997
	AH1	6,001,978	12/14/1999	Edgington <i>et al.</i>			04/22/1997
	AI1	6,004,555	12/21/1999	Thorpe <i>et al.</i>			06/07/1995
	AJ1	6,036,955	03/14/2000	Thorpe <i>et al.</i>			06/07/1995
	AK1	6,093,399	07/25/2000	Thorpe <i>et al.</i>			06/07/1995
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	JP 05-244988	09/24/1993	Japan			Yes X No
	AM1	WO 94/05328	03/17/1994	WIPO			Yes No
	AN1	WO 96/01653	01/25/1996	WIPO			Yes No
	AO1	WO 97/09063	03/13/1997	WIPO			Yes No
	AP1	WO 98/40408	09/17/1998	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	1	Bromberg, M.E., <i>et al.</i> , "Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation," <i>Proc. Natl. Acad. Sci. USA</i> 92:8205-8209, National Academy of Sciences (1995)				
	AS	1	Callander, N.S., <i>et al.</i> , "Immunohistochemical Identification of Tissue Factor in Solid Tumors," <i>Cancer</i> 70:1194-1201, J.B. Lippincott Company (1992)				
	AT	1	Carson, S.D., <i>et al.</i> , "An Inhibitory Monoclonal Antibody Against Human Tissue Factor," <i>Blood</i> 70:490-493, American Society of Hematology (1987)				
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	6,555,319 B2	04/29/2003	Wong <i>et al.</i>			04/16/1999
	AB2	2003/0082636 A1	05/01/2003	Wong <i>et al.</i>			11/12/2002
	AC2	2003/0109680 A1	06/12/2003	Wong <i>et al.</i>			11/21/2001
	AD2	2003/0119075 A1	06/26/2003	Kirchhofer <i>et al.</i>			03/08/2001
	AE2	2003/0124117 A1	07/03/2003	Refino <i>et al.</i>			06/07/2002
	AF2	2003/0176664 A1	09/18/2003	Jiao <i>et al.</i>			12/04/2002
	AG2	2004/0044187 A1	03/04/2004	Sato <i>et al.</i>			06/16/2003
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 01/02439 A1	01/11/2001	WIPO			Yes No
	AM2	WO 01/27079 A2	04/19/2001	WIPO			Yes No
	AN2	JP 2001-213804	08/07/2001	Japan			Yes X No
	AO2	WO 01/70984 A2	09/27/2001	WIPO			Yes No
	AP2	WO 03/037911 A2	05/08/2003	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Carson, S.D., <i>et al.</i> , "Monoclonal Antibodies Against Bovine Tissue Factor, Which Block Interaction With Factor VII _a ," <i>Blood</i> 66:152-156, American Society of Hematology (1985)
	AS	2	Contrino, J., <i>et al.</i> , " <i>In situ</i> detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease," <i>Nat. Med.</i> 2:209-215, Nature Publishing Company (1996)
	AT	2	Drake, T.A., <i>et al.</i> , "Selective Cellular Expression of Tissue Factor in Human Tissues," <i>Am. J. Pathol.</i> 134:1087-1097, American Association of Pathologists (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1670002/JUK/AWL
FIRST NAMED INVENTOR
Wang, B.
FILING DATE
April 5, 2004

APPLICATION NO.
10/816,938
ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 03/093422 A2	11/13/2003	WIPO			Yes No
	AM3	WO 03/103711 A1	12/18/2003	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Ewan, V., <i>et al.</i> , "Production of a Monoclonal Antibody with Anticoagulant Activity for Human Tissue Factor," <i>Fed. Proc.</i> 42:521, Federation of American Societies For Experimental Biology (1983)
	AS	<u>3</u>	Ewan, V.A., and Rickles, F.R., "Production of a Monoclonal Antibody with Anticoagulant Activity for Human Tissue Factor," <i>J. Thromb. Haemost.</i> 50:406, Blackwell Pub (1983)
	AT	<u>3</u>	Fiore, M.M., <i>et al.</i> , "An Unusual Antibody That Blocks Tissue Factor/Factor VIIa Function by Inhibiting Cleavage Only of Macromolecular Substrates," <i>Blood</i> 80:3127-3134, American Society of Hematology (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Hancock, W.W., <i>et al.</i> , "Immunohistological Studies with a Monoclonal Antibody to Human Tissue Factor : Normal Distribution and Usefulness as a Marker for Activated Macrophages," <i>Pathology</i> 16:479-480, Abstracts of Annual Meeting (1984)
	AS	<u>4</u>	Hu, T., <i>et al.</i> , "Procoagulant Activity in Cancer Cells is Dependent on Tissue Factor Expression," <i>Oncol. Res.</i> 6:321-327, Elsevier Science (1994)
	AT	<u>4</u>	Hu, Z., and Garen, A., "Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer," <i>Proc. Natl. Acad. Sci. USA</i> 98:12180-12185, National Academy of Sciences (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Hu, Z., <i>et al.</i> , "Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model," <i>Proc. Natl. Acad. Sci. USA</i> 96:8161-8166, National Academy of Sciences (1999)
	AS	<u>5</u>	Koomagi, R., and Volm, M., "Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis," <i>Int. J. Cancer</i> 79:19-22, Wiley-Liss (1998)
	AT	<u>5</u>	Morrissey, J.H., <i>et al.</i> , "EC11 CD142(tissue factor) Workshop Panel Report," <i>Leucocyte Typing</i> 6:742-746, Garland Pub. (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>6</u>	Morrissey, J.H., <i>et al.</i> , "Monoclonal antibody analysis of purified and cell-associated tissue factor," <i>Thromb. Res.</i> 52:247-261, Pergamon Press (1988)
AS	<u>6</u>	Ngo, C., <i>et al.</i> , "CNTO 89, a Humanized Anti-Tissue Factor Monoclonal Antibody, Inhibits Lung Metastasis and Tumor Growth In MDA-MB-231 Breast Cancer Xenograft Models," <i>Pathophysiol. Haemost. Thromb.</i> 33, supplement 1: 71, Radnor (September 2003)
AT	<u>6</u>	Nishi, T., <i>et al.</i> , "Tissue Factor Expressed in Pituitary Adenoma Cells Contributes to the Development of Vascular Events in Pituitary Adenomas," <i>Cancer</i> 86:1354-1361, Wiley (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>I</u>	Rao, L.V., "Characterization of Anti-Tissue Factor Antibody and Its Use in Immunoaffinity Purification of Human Tissue Factor," <i>Thromb. Res.</i> 51:373-384, Pergamon Press (1988)
	AS	<u>I</u>	Sawada, M., <i>et al.</i> , "Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis," <i>Br. J. Cancer</i> 79:472-477, Harcourt Brace and Company Ltd (1999)
	AT	<u>I</u>	Seto, S., <i>et al.</i> , "Tissue Factor Expression in Human Colorectal Carcinoma: Correlation with Hepatic Metastasis and Impact on Prognosis," <i>Cancer</i> 88:295-301, Wiley (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	Shen, B., <i>et al.</i> , "Vascular Endothelial Growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells," <i>J. Biol. Chem.</i> 276:5281-5286, American Society for Biochemistry and Molecular Biology (2001)
	AS	<u>8</u>	Shigemori, C., <i>et al.</i> , "Tissue Factor Expression and Metastatic Potential of Colorectal Cancer," <i>J. Thromb. Haemost.</i> 80:894-898, Blackwell Pub. (1998)
	AT	<u>8</u>	Tanaka, H., <i>et al.</i> , "Purification of Glycosylated Apoprotein of Tissue Factor from Human Brain and Inhibition of its Procoagulant Activity by a Specific Antibody," <i>Thromb. Res.</i> 40:745-756, Pergamon Press (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>9</u>	Zacharski, L.R., <i>et al.</i> , "Coagulation-Cancer Interaction <i>In Situ</i> in Renal Cell Carcinoma," <i>Blood</i> 68:394-399, American Society of Hematology (1986)
	AS	<u>9</u>	Zacharski, L.R., <i>et al.</i> , "Occurrence of Fibrin and Tissue Factor Antigen in Human Small Cell Carcinoma of the Lung," <i>Cancer Res.</i> 43:3963-3968, American Association for Cancer Research (1983)
	AT	<u>9</u>	Zeldis, S.M., <i>et. al.</i> , "Tissue factor (Thromboplastin): Localization to Plasma Membranes by Peroxidase-Conjugated Antibodies," <i>Science</i> 175:766-768, American Association for the Advancement of Science (1972)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Patent Abstracts of Japan, English Language Abstract of JP 05-244988 (Document AL1)
	AS	<u>10</u>	Patent Abstracts of Japan, English Language Abstract of JP 2001-213804 (Document AN2)
	AT		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

ATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT	10	Abdulkadir, S.A., et. al., "Tissue factor expression and angiogenesis in human prostate carcinoma," <i>Hum. Pathol.</i> 31:403-405, W. B. Saunders (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>11</u>	Ahern, S.M., <i>et. al.</i> , "Regulation of Human Tissue Factor Expression by mRNA Turnover," <i>J. Biol. Chem.</i> 268:2154-2159, The American Society for Biochemistry and Molecular Biology, Inc. (1993)
AS	<u>11</u>	Akashi, T., <i>et. al.</i> , "Tissue factor expression and prognosis in patients with metastatic prostate cancer," <i>Urology</i> 62:1078-1082, Elsevier Science (December 2003)
AT	<u>11</u>	Belting, M., <i>et. al.</i> , "Regulation of angiogenesis by tissue factor cytoplasmic domain signaling," <i>Nature Medicine</i> 10:502-509, Nature Publishing Group (May 2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Cao, Y., "Antiangiogenic cancer therapy," <i>Semin Cancer Biol.</i> 14:139-145, Academic Press (April 2004)
	AS	<u>12</u>	Carmeliet, P., and Jain, R.K., "Angiogenesis in cancer and other diseases," <i>Nature</i> 407:249-257, Macmillan Magazines Ltd (2000)
	AT	<u>12</u>	Carmeliet, P., and Collen, D., "Molecules in focus: Tissue factor," <i>Int. J. Biochem. Cell Biol.</i> 30:661-667, Pergamon Press (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Carmeliet, P., <i>et. al.</i> , "Role of tissue factor in embryonic blood vessel development," <i>Nature</i> 383:73-75, Nature Publishing Group (1996)
	AS	<u>13</u>	Chiang, H.-S., <i>et. al.</i> , "Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation," <i>Br. J. Cancer</i> 78:1121-1127, Cancer Research Campaign (1998)
	AT	<u>13</u>	Fleck, R.A., <i>et. al.</i> , "Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody," <i>Thromb Res.</i> 59:421-437 (1990)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWL
FIRST NAMED INVENTOR
Wang, B.
FILING DATE
April 5, 2004APPLICATION NO.
10/816,938
ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>14</u>	Förster, Y., <i>et. al.</i> , "Tissue specific expression and serum levels of human tissue factor in patients with urological cancer," <i>Cancer Lett.</i> 193:65-73, Elsevier Science Ireland (April 2003)
	AS	<u>14</u>	Guan, M., <i>et. al.</i> , "Quantitative Reverse Transcription-PCR Measurement of Tissue Factor mRNA in Glioma," <i>Mol. Biotechnol.</i> 20:123-129, Humana Press (February 2002)
	AT	<u>14</u>	Hu, Z., and Garen, A., "Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97:9221-9225, National Academy of Sciences (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Huang, X., <i>et. al.</i> , "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> 275:547-550, American Association for the Advancement of Science (1997)
	AS	<u>15</u>	Ishibashi, H., <i>et. al.</i> , "Sp1 Decoy Transfected to Carcinoma Cells Suppresses the Expression of Vascular Endothelial Growth Factor, Transforming Growth Factor β_1 , and Tissue Factor and Also Cell Growth and Invasion Activities," <i>Cancer Res.</i> 60:6531-6536, American Association for Cancer Research (2000)
	AT	<u>15</u>	Keller, T., <i>et. al.</i> , "Tissue factor is the only activator of coagulation in cultured human lung cancer cells," <i>Lung Cancer</i> 31:171-179, Elsevier Scientific Publishers (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLFIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004APPLICATION NO.
10/816,938ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Kirschmann, D.A., <i>et. al.</i> , "Differentially expressed genes associated with the metastatic phenotype in breast cancer," <i>Breast Cancer Res. Treat.</i> 55:127-136, Kluwer Academic Publishers (1999)
	AS	<u>16</u>	Lee, A.Y., "Cancer and thromboembolic disease: pathogenic mechanisms," <i>Cancer Treat. Rev.</i> 28:137-140, Elsevier Science Ltd (June 2002)
	AT	<u>16</u>	Lip, G.Y., <i>et. al.</i> , "Cancer and the prothrombotic state," <i>Lancet Oncol.</i> 3:27-34, Lancet Pub. Group (January 2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Lwaleed, B.A., <i>et. al.</i> , "The biology and tumour-related properties of monocyte tissue factor," <i>J. Pathol.</i> 193:3-12, John Wiley & Sons (2000)
	AS	<u>17</u>	Lykke, J., and Nielson, H.J., "The role of tissue factor in colorectal cancer," <i>Eur. J. Surg. Oncol.</i> 29:417-422, Academic Press (June 2003)
	AT	<u>17</u>	Minamiya, Y., <i>et. al.</i> , " Expression of tissue factor mRNA and invasion of blood vessels by tumor cells in non-small cell lung cancer," <i>Surg. Today</i> 34:1-5, Springer International (January 2004)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Mueller, B.M., <i>et. al.</i> , "Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:11832-11836, National Academy of Sciences (1992)
	AS	<u>18</u>	Müller, M., <i>et. al.</i> , "Cellular localization of tissue factor in human breast cancer cell lines," <i>Virchows Arch. B Cell Pathol.</i> 64:265-269, Springer-Verlag (1993)
	AT	<u>18</u>	Nilsson, F., <i>et. al.</i> , "Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice," <i>Cancer Res.</i> 61:711-716, American Association for Cancer Research (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>19</u>	Ohta, S., <i>et. al.</i> , "Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer," <i>Anticancer Res.</i> 22:2991-2996, J.G. Delinassios, Anticancer Research (September-October 2002)
	AS	<u>19</u>	Ran, S., <i>et. al.</i> , "Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature," <i>Cancer Res.</i> 58:4646-4653, American Association for Cancer Research (1998)
	AT	<u>19</u>	Ruf, W., "Tissue Factor-Dependent Signaling in Tumor Biology," <i>Pathophysiol Haemost Thromb.</i> 33:28-30, Karger (September 2003)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Ruf, W., and Mueller, B.M., "Tissue factor in cancer angiogenesis and metastasis," <i>Curr. Opin. Hematol.</i> 3:379-384, Rapid Science Publishers (1996)
	AS	<u>20</u>	Semeraro, N., and Colucci, M., "Tissue factor in health and disease," <i>Thromb. Haemost.</i> 78:759-764, Schattauer (1997)
	AT	<u>20</u>	Shoji, M., et. al., "Activation of Coagulation and Angiogenesis in Cancer: <i>Immunohistochemical Localization in Situ of Clotting Proteins and Vascular Endothelial Growth Factor in Human Cancer</i> ," <i>Am. J. Pathol.</i> 152:399-411, American Society for Investigative Pathology (1998)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1670002/JUK/AWL	APPLICATION NO. 10/816,938
	FIRST NAMED INVENTOR Wang, B.	
	FILING DATE April 5, 2004	ART UNIT 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Ueno, T., <i>et. al.</i> , "Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration," <i>Br. J. Cancer</i> 83:164-170, Cancer Research Campaign (2000)
	AS	<u>21</u>	Volm, M., <i>et. al.</i> , "Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype," <i>Anticancer Res.</i> 22:2321-2324, J.G. Delinassios, Anticancer Research (July-August 2002)
	AT	<u>21</u>	Zhang, Y., <i>et. al.</i> , "Tissue Factor Controls the Balance of Angiogenic and Antiangiogenic Properties of Tumor Cells in Mice," <i>J. Clin. Invest.</i> 94:1320-1327, American Society for Clinical Investigation (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1861.1670002/JUK/AWLAPPLICATION NO.
10/816,938FIRST NAMED INVENTOR
Wang, B.FILING DATE
April 5, 2004ART UNIT
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Zucker, S., <i>et. al.</i> , "Vascular Endothelial Growth Factor Induces Tissue Factor and Matrix Metalloproteinase Production in Endothelial Cells: Conversion of Prothrombin to Thrombin Results in Progelatinase A Activation and Cell Proliferation," <i>Int. J. Cancer</i> 75:780-786, Wiley-Liss, Inc. (1998)
	AS	<u>22</u>	Schwirzke, M., <i>et. al.</i> , "New Genes Potentially Involved in Breast Cancer Metastasis," <i>Anticancer Res.</i> 19:1801-1814, J.G. Delinassios, Anticancer Research (1999)
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.